{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:28:44Z","timestamp":1790036924801,"version":"4.0.1"},"reference-count":93,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2001,12,1]],"date-time":"2001-12-01T00:00:00Z","timestamp":1007164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2001,12]]},"DOI":"10.1053\/ctrv.2002.0244","type":"journal-article","created":{"date-parts":[[2002,9,19]],"date-time":"2002-09-19T13:54:50Z","timestamp":1032443690000},"page":"339-350","source":"Crossref","is-referenced-by-count":9,"title":["Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide"],"prefix":"10.1053","volume":"27","author":[{"given":"E.J.","family":"Estlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Yule","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.P.","family":"Lowis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/ctrv.2002.0244_RF1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(95)90164-7","article-title":"Intensification of treatment and survival in all children with lymphoblastic leukaemia: Results of UK Medical Research Council trial UKALL X","volume":"345","author":"Chessells","year":"1995","journal-title":"Lancet"},{"key":"10.1053\/ctrv.2002.0244_RF2","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood.V84.9.3122.3122","article-title":"Chemotherapy in 998 unselected childhood acute lymphoblastic leukaemia patients. Results and conclusions of the multicentre trial ALL-BFM 86","volume":"84","author":"Reiter","year":"1994","journal-title":"Blood"},{"key":"10.1053\/ctrv.2002.0244_RF3","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJM199806043382304","article-title":"Augmented post-induction therapy for children with high-risk acute lymphoblastic leukaemia and a slow response to initial therapy","volume":"338","author":"Nachman","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1053\/ctrv.2002.0244_RF4","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/oxfordjournals.annonc.a057856","article-title":"Comparative results of two intensive treatment programs for acute lymphoblastic leukaemia: The Berlin\u2013Frankfurt\u2013Munster and Dana-Farber Cancer Institute protocols","volume":"2","author":"Niemeyer","year":"1991","journal-title":"Ann Oncol"},{"key":"10.1053\/ctrv.2002.0244_RF5","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1200\/JCO.1994.12.9.1939","article-title":"Comparison of two schedules of intermediate-dose methotrexate and cytarabine consolidation for childhood B-precursor acute lymphoblastic leukaemia: A Pediatric Oncology Group Study","volume":"12","author":"Land","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2002.0244_RF6","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1056\/NEJM199802193380803","article-title":"Conventional compared with individualised chemotherapy for childhood acute lymphoblastic leukaemia","volume":"338","author":"Evans","year":"1998","journal-title":"N. Engl J Med"},{"key":"10.1053\/ctrv.2002.0244_RF7","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(98)04058-6","article-title":"Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood","volume":"352","author":"van Dongen","year":"1998","journal-title":"Lancet"},{"key":"10.1053\/ctrv.2002.0244_RF8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1365-2141.1998.00574.x","article-title":"Minimal residual disease analysis for the prediction of relapse in children with standard-risk acute lymphoblastic leukaemia","volume":"100","author":"Goulden","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1053\/ctrv.2002.0244_RF9","first-page":"213","article-title":"Cytidine analogues","author":"Chabner","year":"1996"},{"key":"10.1053\/ctrv.2002.0244_RF10","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1172\/JCI111741","article-title":"Cytosine arabinosaide transport and metabolism in acute leukaemia and T cell lymphoblastic lymphoma","volume":"75","author":"Wiley","year":"1985","journal-title":"J Clin Invest"},{"key":"10.1053\/ctrv.2002.0244_RF11","first-page":"34","article-title":"Biochemical and cellular pharmacology of cytosine arabinoside","volume":"12","author":"Kufe","year":"1985","journal-title":"Semin Oncol"},{"key":"10.1053\/ctrv.2002.0244_RF12","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/1357-2725(96)00028-3","article-title":"Effects of cytosine arabinosie on human leukaemia cells","volume":"28","author":"Crisp","year":"1996","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1053\/ctrv.2002.0244_RF13","first-page":"1005","article-title":"High molecular weight DNA fragmentation: a critical event in nucleoside analogue-induced apoptosis in leukaemia cells","volume":"1","author":"Huang","year":"1995","journal-title":"Clin Cancer Res"},{"key":"10.1053\/ctrv.2002.0244_RF14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/bjc.1991.333","article-title":"In vitro drug sensitivity of normal peripheral blood lymphocytes and childhood leukaemic cells form bone marrow and peripheral blood","volume":"64","author":"Kaspers","year":"1991","journal-title":"Br J Cancer"},{"key":"10.1053\/ctrv.2002.0244_RF15","first-page":"3005","article-title":"Saturation of1-\u03b2-D-arabinofuranoylcytosine 5'-triphosphate accumulation in leukaemia cells during high-dose 1-\u03b2-D-arabinofuranoylcytosine therapy","volume":"47","author":"Plunkett","year":"1987","journal-title":"Cancer Res"},{"key":"10.1053\/ctrv.2002.0244_RF16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/(SICI)1096-911X(199606)26:6<397::AID-MPO5>3.0.CO;2-C","article-title":"Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukaemia","volume":"26","author":"Boos","year":"1996","journal-title":"Med Pediatr Oncol"},{"key":"10.1053\/ctrv.2002.0244_RF17","first-page":"6786","article-title":"Biochemical pharmacology of high dose 1-\u03b2- D -arabinofuranosylcytosine in childhood acute leukaemia","volume":"47","author":"Avramis","year":"1987","journal-title":"Cancer Res"},{"key":"10.1053\/ctrv.2002.0244_RF18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/(SICI)1097-0215(19960328)66:1<29::AID-IJC6>3.0.CO;2-0","article-title":"The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in culture human leukaemia cells","volume":"66","author":"Takemura","year":"1996","journal-title":"Int J Cancer"},{"key":"10.1053\/ctrv.2002.0244_RF19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1124\/mol.52.1.155","article-title":"Differences in folylpolyglutamyl synthase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukaemic lymphoblasts: Mechanisms for lineage differences in methotrexate polyglutamation and cytotoxicity","volume":"52","author":"Galpin","year":"1997","journal-title":"Mol Pharmacol"},{"key":"10.1053\/ctrv.2002.0244_RF20","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/0006-2952(96)00041-X","article-title":"Apoptosis as a mechanism of cell death induced by different chemotherapeutic drugs in human leukaemic T-lymphocytes","volume":"51","author":"da Silva","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"10.1053\/ctrv.2002.0244_RF21","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1182\/blood.V86.10.3861.bloodjournal86103861","article-title":"In vitro cellular drug resistance in children with relapsed\/refractory acute lymphoblastic leukaemia","volume":"86","author":"Klumper","year":"1995","journal-title":"Blood"},{"key":"10.1053\/ctrv.2002.0244_RF22","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/clpt.1986.178","article-title":"Oral 6-mercaptopurine in childhood leukaemia: Parent drug pharmacokinetics and active metabolite concentrations","volume":"40","author":"Lennard","year":"1986","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/ctrv.2002.0244_RF23","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1124\/mol.54.1.78","article-title":"Etoposide targets topoisomerase IIalpha and IIbeta in leukaemic cells: isoform-specific cleavable complexes visualised and quantified in situ by a novel immunofluorescence technique","volume":"54","author":"Willmore","year":"1998","journal-title":"Mol Pharmacol"},{"key":"10.1053\/ctrv.2002.0244_RF24","first-page":"1463","article-title":"Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases II alpha (p170) and II beta (p180)","volume":"50","author":"Cornarotti","year":"1996","journal-title":"Mol Pharmacol"},{"key":"10.1053\/ctrv.2002.0244_RF25","doi-asserted-by":"crossref","first-page":"(Suppl): S26","DOI":"10.1007\/BF00684860","article-title":"Structure-activity relationships of VP-16 analogues","volume":"34","author":"Long","year":"1994","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/ctrv.2002.0244_RF26","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood.V90.11.4283","article-title":"Comparison of caspase activation and sub-cellular localisation in HL-60 and K562 cells undergoing etoposide-induced apoptosis","volume":"90","author":"Martins","year":"1997","journal-title":"Blood"},{"key":"10.1053\/ctrv.2002.0244_RF27","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1007\/BF00684861","article-title":"Topoisomerase expression in cancer cells and clinical samples","volume":"34","author":"Doyle","year":"1994","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/ctrv.2002.0244_RF28","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/BF00253972","article-title":"Etoposide-induced DNA cleavage in human leukaemia cells","volume":"20","author":"Edwards","year":"1987","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/ctrv.2002.0244_RF29","first-page":"149","article-title":"Development and properties of an etoposide-resistant human leukaemic CCRF-CEM cell line","volume":"5","author":"Patel","year":"1990","journal-title":"Anti Cancer Drug Des"},{"key":"10.1053\/ctrv.2002.0244_RF30","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/bjc.1994.131","article-title":"Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells","volume":"69","author":"Ritke","year":"1994","journal-title":"Br J Cancer"},{"key":"10.1053\/ctrv.2002.0244_RF31","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/0959-8049(95)00026-F","article-title":"Exposure and schedule dependency of etoposide in neuroblastoma sand leukaemia cells in vitro","volume":"31A","author":"Lowis","year":"1995","journal-title":"Eur J Cancer"},{"key":"10.1053\/ctrv.2002.0244_RF32","first-page":"1653","article-title":"Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukaemia","volume":"9","author":"Klumper","year":"1995","journal-title":"Leukaemia"},{"key":"10.1053\/ctrv.2002.0244_RF33","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/sj.leu.2400729","article-title":"Optimal immunocytochemical and flow cytometric detection of P-gp, MRP and LRP in childhood acute lymphoblastic leukaemia","volume":"11","author":"Den Boer","year":"1997","journal-title":"Leukaemia"},{"key":"10.1053\/ctrv.2002.0244_RF34","first-page":"43","article-title":"Relationship between DNA cross-links, cell cycle and apoptosis in Burkitt's lymphoma cell lines differing in sensitivity to nitrogen mustard","volume":"3","author":"O'Connor","year":"1991","journal-title":"Cell Growth Diff"},{"key":"10.1053\/ctrv.2002.0244_RF35","first-page":"233","article-title":"Comparison of the sensitivity of normal haematopoetic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo","volume":"37","author":"Bruce","year":"1966","journal-title":"J Nat Cancer Inst"},{"key":"10.1053\/ctrv.2002.0244_RF36","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00007890-197209000-00010","article-title":"The comparative effects of selected cytotoxic agents on transplanted haematopoietic cells","volume":"14","author":"Sensenbrenner","year":"1972","journal-title":"Transplantation"},{"key":"10.1053\/ctrv.2002.0244_RF37","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/1097-0142(19840915)54:1+<1179::AID-CNCR2820541315>3.0.CO;2-P","article-title":"Pharmacokinetics of \u2018activated\u2019 cyclophosphamide and therapeutic efficacies","volume":"54","author":"Voelcker","year":"1984","journal-title":"Cancer"},{"key":"10.1053\/ctrv.2002.0244_RF38","first-page":"5994","article-title":"III. Influence of schedule of alkylating agent cytotoxicity in vitro and in vivo","volume":"49","author":"Teicher","year":"1989","journal-title":"Cancer Res"},{"key":"10.1053\/ctrv.2002.0244_RF39","first-page":"613","article-title":"Alkylating agent resistance in paediatric oncology","volume":"4","author":"Yule","year":"1997","journal-title":"Int J Pediatr Hematol Oncol"},{"key":"10.1053\/ctrv.2002.0244_RF40","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1200\/JCO.1998.16.8.2840","article-title":"Consolidation therapy with antimetabolite-based therapy in standard risk acute lymphoblastic leukaemia of childhood: A Pediatric Oncology Group study","volume":"16","author":"Harris","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2002.0244_RF41","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/(SICI)1096-911X(199804)30:4<233::AID-MPO5>3.0.CO;2-H","article-title":"High-dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukemia: the Children's Cancer Group experience","volume":"30","author":"Harris","year":"1998","journal-title":"Med Pediatr Oncol"},{"key":"10.1053\/ctrv.2002.0244_RF42","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1200\/JCO.1993.11.5.839","article-title":"Extended triple intrathecal chemotherapy trial for prevention of CNS in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukaemia: A Pediatric Oncology Group Study","volume":"11","author":"Pullen","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2002.0244_RF43","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/JCO.1983.1.9.546","article-title":"Effect of dose and schedule on pharmacokinetics of high-dose cytosine arabinoside in plasma and cerebrospinal fluid","volume":"1","author":"Slevin","year":"1983","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2002.0244_RF44","first-page":"15","article-title":"Individualised dosages of chemotherapy as a strategy to improve response for acute lymphoblastic leukaemia","volume":"28","author":"Evans","year":"1991","journal-title":"Semin Hematol"},{"key":"10.1053\/ctrv.2002.0244_RF45","first-page":"241","article-title":"Pharmacology studies of 1-\u03b2-D-arabinofuranosylcytosine in pediatric patients with leukaemia and lymphoma after a biochemically optimal regimen of loading bolus plus continuous infusion of the drug","volume":"49","author":"Avramis","year":"1989","journal-title":"Cancer Res"},{"key":"10.1053\/ctrv.2002.0244_RF46","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s002800050536","article-title":"NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukaemia","volume":"39","author":"Periclou","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/ctrv.2002.0244_RF47","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00686248","article-title":"Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside","volume":"29","author":"DeAngelis","year":"1992","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/ctrv.2002.0244_RF48","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/j.1552-4604.1987.tb03025.x","article-title":"Pharmacokinetic studies of intermediate-to high-dose 1- beta-D-arabinofuranosylcytosine in children with acute leukaemia and lymphoma","volume":"27","author":"Takashima","year":"1987","journal-title":"J Clin Pharmacol"},{"key":"10.1053\/ctrv.2002.0244_RF49","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/cpt1971126944","article-title":"Clinical pharmacology of 1-\u03b2-D-arabinofuranosylcytosine","volume":"12","author":"Ho","year":"1971","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/ctrv.2002.0244_RF50","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF00254537","article-title":"Pharmacokinetics of teniposide (VM26) and etoposide (VP16-213) in children with cancer","volume":"7","author":"Evans","year":"1982","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/ctrv.2002.0244_RF51","first-page":"1235","article-title":"Teniposide (VM26) disposition in children with leukaemia","volume":"44","author":"Sinulke","year":"1984","journal-title":"Cancer Res"},{"key":"10.1053\/ctrv.2002.0244_RF52","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/bjc.1998.385","article-title":"A study of the feasibility and accuracy of pharmacologically guided etoposide dosing in children","volume":"77","author":"Lowis","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1053\/ctrv.2002.0244_RF53","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.1996.14.2.399","article-title":"Etoposide achieves potentially cytotoxic concentrations in the CSF of children with acute lymphoblastic leukaemia","volume":"14","author":"Relling","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2002.0244_RF54","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.leu.2401310","article-title":"Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T-cell acute lymphoblastic leukaemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group Study","volume":"13","author":"Amylon","year":"1999","journal-title":"Leukaemia"},{"key":"10.1053\/ctrv.2002.0244_RF55","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1200\/JCO.1999.17.2.445","article-title":"Treatment outcome and prognostic factors for infants with acute lymphoblastic leukaemia treated on two consecutive trials of the Children's Cancer Group","volume":"17","author":"Reaman","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2002.0244_RF56","first-page":"803","article-title":"Cyclophosphamide metabolism in children","volume":"55","author":"Yule","year":"1995","journal-title":"Cancer Res"},{"key":"10.1053\/ctrv.2002.0244_RF57","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2125.1996.tb00153.x","article-title":"Cyclophosphamide pharmacokinetics in children","volume":"41","author":"Yule","year":"1996","journal-title":"Br J Clin Pharmacol"},{"key":"10.1053\/ctrv.2002.0244_RF58","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1200\/JCO.1997.15.5.1885","article-title":"Dose escalation of cyclophosphamide in patients with breast cancer: Consequences for pharmacokinetics and metabolism","volume":"15","author":"Busse","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2002.0244_RF59","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/1097-0142(19870701)60:1<5::AID-CNCR2820600103>3.0.CO;2-D","article-title":"A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5g to 33.6g\/m2 in children with acute lymphoblastic leukaemia","volume":"60","author":"Borsi","year":"1987","journal-title":"Cancer"},{"key":"10.1053\/ctrv.2002.0244_RF60","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1056\/NEJM198602203140803","article-title":"Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukaemia","volume":"314","author":"Evans","year":"1986","journal-title":"New Engl J Med"},{"key":"10.1053\/ctrv.2002.0244_RF61","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/mpo.2950240303","article-title":"Pharmacokinetics of HD-MTX in infants, children and adolescents with non-B acute lymphoblastic leukaemia","volume":"24","author":"Donelli","year":"1995","journal-title":"Med Pediatr Oncol"},{"key":"10.1053\/ctrv.2002.0244_RF62","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM197507242930402","article-title":"Methotrexate distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections","volume":"293","author":"Shapiro","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1053\/ctrv.2002.0244_RF63","first-page":"703","article-title":"Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in non-toxic patients after lumbar injection","volume":"61","author":"Bleyer","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"10.1053\/ctrv.2002.0244_RF64","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.1994.12.7.1383","article-title":"Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk Non-T, Non-B acute lymphoblastic leukaemia: A Pediatric Oncology group study","volume":"12","author":"Camitta","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2002.0244_RF65","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s002280050339","article-title":"Pharmacokinetics and distribution of 6-mercaptopurine administered intravenously in children with lymphoblastic leukaemia","volume":"53","author":"Jacqz-Aigrain","year":"1997","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1053\/ctrv.2002.0244_RF66","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/1097-0142(196803)21:3<341::AID-CNCR2820210302>3.0.CO;2-F","article-title":"Cytosine arabinoside. Results of a co-operative study in acute childhood leukaemia","volume":"21","author":"Howard","year":"1968","journal-title":"Cancer"},{"key":"10.1053\/ctrv.2002.0244_RF67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1097-0142(197001)25:1<1::AID-CNCR2820250102>3.0.CO;2-N","article-title":"Prolonged infusion of arabinosylcytosine in childhood leukaemia","volume":"25","author":"Wang","year":"1970","journal-title":"Cancer"},{"key":"10.1053\/ctrv.2002.0244_RF68","first-page":"1587","article-title":"A pilot study of high-dose 1-beta-D-aabinofuranosylcytosine for acute leukaemia and refractory lymphoma: clinical response and pharmacology","volume":"42","author":"Early","year":"1982","journal-title":"Cancer Res"},{"key":"10.1053\/ctrv.2002.0244_RF69","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1200\/JCO.1984.2.10.1092","article-title":"Continuous infusion high-dose cytosine arabinoside in refractory childhood leukaemia","volume":"2","author":"Ochs","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2002.0244_RF70","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1007\/BF00684870","article-title":"Epipodophyllotoxins in the treatment of childhood cancer","volume":"34","author":"Rivera","year":"1994","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/ctrv.2002.0244_RF71","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF00254526","article-title":"VP16-213 (Etoposide). A critical review of its activity","volume":"7","author":"Cavalli","year":"1982","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1053\/ctrv.2002.0244_RF72","first-page":"1755","article-title":"Phase II study of VP-16-123 in childhood malignant disease: A Children's Cancer Study Group Report","volume":"63","author":"Chard","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1053\/ctrv.2002.0244_RF73","first-page":"265","article-title":"Phase I-II trial of VM-26 (NSC-122819) in the treatment of children with late-stage leukaemia","volume":"60","author":"Rosenstock","year":"1976","journal-title":"Cancer Treat Rep"},{"key":"10.1053\/ctrv.2002.0244_RF74","first-page":"977","article-title":"Phase II study of VM-26 in acute leukaemia, neuroblastoma, and other refractory childhood malignancies: a report from the Children's Cancer Study group","volume":"63","author":"Bleyer","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"10.1053\/ctrv.2002.0244_RF75","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0022-3476(62)80341-2","article-title":"Cyclophosphamide in the treatment of common neoplastic diseases of childhood","volume":"61","author":"Sweeney","year":"1962","journal-title":"J Pediatrics"},{"key":"10.1053\/ctrv.2002.0244_RF76","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jama.1962.03050400032006","article-title":"Clinical evaluation of cyclophosphamide. A new agent for the treatment of children with acute leukaemia","volume":"182","author":"Fernbach","year":"1962","journal-title":"J Am Med Assoc"},{"key":"10.1053\/ctrv.2002.0244_RF77","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1200\/JCO.1992.10.6.995","article-title":"Cyclophosphamide pharmacokinetics: Correlation with cardiac toxicity and tumour response","volume":"10","author":"Ayash","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2002.0244_RF78","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1182\/blood.V50.3.471.471","article-title":"Combination intrathecal therapy for meningeal leukaemia: Two versus three drugs","volume":"50","author":"Sullivan","year":"1997","journal-title":"Blood"},{"key":"10.1053\/ctrv.2002.0244_RF79","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1200\/JCO.1993.11.5.839","article-title":"Extended triple intrathecal chemotherapy trial for prevention of CNS in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukaemia: A Pediatric Oncology Group Study","volume":"11","author":"Pullen","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2002.0244_RF80","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1200\/JCO.1993.11.3.520","article-title":"Prevention of CNS disease in intermediate-risk acute lymphoblastic leukaemia: Comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: A Children's Cancer Group Report","volume":"11","author":"Tubergen","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2002.0244_RF81","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1182\/blood.V92.2.411","article-title":"Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukaemia","volume":"92","author":"Pui","year":"1998","journal-title":"Blood"},{"key":"10.1053\/ctrv.2002.0244_RF82","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1002\/cpt196673332","article-title":"The role of vincristine in the treatment of childhood acute leukaemia","volume":"7","author":"Karon","year":"1966","journal-title":"Clinical Pharmacol Ther"},{"key":"10.1053\/ctrv.2002.0244_RF83","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/mpo.2950190404","article-title":"Association between delivered drug dose and outcome for children with acute lymphoblastic leukaemia and unfavourable presenting features","volume":"19","author":"Gaynon","year":"1991","journal-title":"Med Pediatr Oncol"},{"key":"10.1053\/ctrv.2002.0244_RF84","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1200\/JCO.1997.15.6.2222","volume":"15","author":"Nachman","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2002.0244_RF85","first-page":"45","article-title":"Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a Phase I\/II study in pediatric patients with relapsed leukaemia","volume":"4","author":"Avramis","year":"1985","journal-title":"Clin Cancer Res"},{"key":"10.1053\/ctrv.2002.0244_RF86","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1200\/JCO.1996.14.10.2803","article-title":"Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukaemia","volume":"14","author":"Winick","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2002.0244_RF87","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1040-8428(98)00015-8","article-title":"Use of L-asparaginase in childhood ALL","volume":"28","author":"Muller","year":"1998","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1053\/ctrv.2002.0244_RF88","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/bmj.304.6832.951","article-title":"Epipodophyllotoxins, alkylating agents, and radiation risk of secondary leukaemia after childhood cancer","volume":"304","author":"Hawkins","year":"1992","journal-title":"Br Med J"},{"key":"10.1053\/ctrv.2002.0244_RF89","first-page":"3730","article-title":"Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumours","volume":"53","author":"Motzer","year":"1993","journal-title":"Cancer Res"},{"key":"10.1053\/ctrv.2002.0244_RF90","first-page":"213","article-title":"Intermittent continuous IV infusion of high-dose cyclophosphamide for remission induction in acute leukaemia","volume":"65","author":"Solidozo","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"10.1053\/ctrv.2002.0244_RF91","first-page":"293","article-title":"Continuous infusion cyclophosphamide plus vincristine cytosine-arabinoside and prednisolone for refractory acute lymphoblastic leukaemia in adults","volume":"76","author":"Ciolli","year":"1991","journal-title":"Haematologica"},{"key":"10.1053\/ctrv.2002.0244_RF92","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.1986.4.12.1732","article-title":"Results of treatment of advanced stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and co-ordinated high-dose methotrexate and cytarabine","volume":"4","author":"Murphy","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1053\/ctrv.2002.0244_RF93","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1053\/ctrv.1998.0098","article-title":"The role of pharmacokinetic and phara odynamic studies in the planning of protocols for the treatment of childhood cancer","volume":"25","author":"Burke","year":"1999","journal-title":"Cancer Treat Rev"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737202902446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737202902446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,2,6]],"date-time":"2020-02-06T20:37:18Z","timestamp":1581021438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737202902446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,12]]},"references-count":93,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2001,12]]}},"alternative-id":["S0305737202902446"],"URL":"https:\/\/doi.org\/10.1053\/ctrv.2002.0244","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2001,12]]}}}